Enspire DBS Therapy Announces $10.3M Series B1 for Stroke Rehabilitation
Summary
Enspire DBS Therapy has raised $10.3 million in a Series B1 financing led by Genesys Capital with participation from Cleveland Clinic and JobsOhio Ventures. The company is developing a deep brain stimulation plus rehabilitation therapy for patients with chronic upper-extremity impairment following stroke. Proceeds will support continued enrollment in the RESTORE pivotal clinical trial, a multicenter study evaluating DBS paired with structured outpatient rehabilitation under an FDA-approved Investigational Device Exemption, with interim results expected in mid-2027.
Why it matters
This funding supports one of the most innovative applications of deep brain stimulation: pairing targeted neural stimulation with physical therapy to enhance neuroplasticity and motor recovery after stroke. With approximately 800,000 stroke cases annually in the US and nearly half of survivors requiring assistance with daily activities, restoring arm function represents a massive unmet need. Enspire's approach of combining an established neuromodulation platform with rehabilitation science could create a new treatment paradigm for stroke recovery if the RESTORE trial succeeds.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial